Physician profile
David Eisner
NPI 1477015261
$1,490.14
in general payments reported to CMS, 2019-2025
18 companies · $19.03 in 2025
The $19.03 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $614 · 2024: $857 · 2025: $19.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,490.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $455.60 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $229.11 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $130.50 | 2023-2024 | Rexulti |
| Abbvie INC. | $127.82 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $81.47 | 2023-2024 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $67.78 | 2023-2024 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $65.67 | 2023-2024 | Spravato |
| Astellas Pharma US INC | $53.26 | 2023 | Veozah |
| Abbott Laboratories | $50.61 | 2023-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $48.69 | 2024 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.37 | 2024 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.61 | 2023-2024 | Ofev, Jardiance |
| Amgen INC. | $23.95 | 2024 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $19.59 | 2023 | Verquvo, Belsomra |
| Exact Sciences Corporation | $18.47 | 2024 | Cologuard Collection Kit |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $15.76 | 2023 | Yupelri |
| Ironwood Pharmaceuticals, INC | $14.54 | 2023 | Linzess |
| Antares Pharma, INC. | $14.34 | 2024 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Eisner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.